Instil Bio, Inc.

TIL

Held by 6 specialist biotech funds

High ConvergenceHigh short interest · No specialist buying

6 funds opened new positions. Short interest: 4.0% of float.

Share

BiotechnologyCEO: Bronson CrouchIPO: 2021Website ↗

Instil Bio, Inc., a biopharmaceutical company, focuses on identifying and advancing therapeutic opportunities. It seeks to in-license or acquire and develop additional novel therapeutic candidates in diseases with significant unmet medical need. Instil Bio, Inc. was incorporated in 2018 and is headquartered in Dallas, Texas.

Signal Score

5.5/10

6 funds opened new positions●●

No recent insider activity●●

No upcoming catalysts●●

Held by 6 specialist funds●●

See how each signal contributes — fund overlap, insider activity, catalyst timing, short interest (free trial)

Fund Holdings

6 fund convergence

OrbiMed Advisors

Perceptive Advisors

Tang Capital Management

Commodore Capital

Baker Bros. Advisors

Boxer Capital

Position history (shares)

OrbiMed Advisors

2Q

AI Signal

INSTIL BIO (TIL) — ORBIMED EXIT SIGNAL

OrbiMed's complete exit from Instil Bio, a clinical-stage TIL (tumor-infiltrating lymphocyte) cell therapy company, contrasts sharply with sustained conviction from five other specialist funds (Boxer, Commodore, Tang, Baker Bros., Perceptive). The divergence suggests either differing risk tolerances on Instil's cash runway and regulatory path for its lead program, or OrbiMed's reallocation of capital away from the crowded TIL space.

Unlock full AI analysis — 14-day free trial

2 quarters

Position Trend

Feb 17, 2026

$0

0 funds

May 15, 2026

$0

0 funds

May 29, 2026

$0

0 funds

Aug 14, 2026

$0

0 funds

-100% total institutional value over 16 quarters

Short Interest

High short interest

Short Shares

159K

Change

+1.4%

Days to Cover

10.9

% of Float

4.0%

Settlement

Sep 30, 2026

Short interest over 12 periods

Catalysts

No catalysts tracked.

Be first to know when this name moves

Fund buys and exits, insider activity, and catalyst alerts across 800+ biotechs — free Monday brief.

Activist Filings

SC 13G/APerceptive Advisors0.0%May 15, 2025

SC 13GPerceptive Advisors5.3%Sep 27, 2024

SC 13GBoxer Capital5.5%Sep 27, 2024

SC 13G/ARA Capital Management0.0%Feb 14, 2023

SC 13GRA Capital Management5.9%Jun 22, 2022

Position Details

OrbiMed AdvisorsEXITEDAug 14, 2026

Start free trial for share counts, dollar values & AI analysis

53 more position changes — start your free trial to see dollar values and AI analysis for all of them.

Know which insider moves are real

See who's buying with their own money vs. routine exercises
AI explains why each move matters right now

Start 14-Day Free Trial — $29/mo

Also Held by These Funds

CRNX1 fund MIRM1 fund GLUE1 fund IMTX1 fund ABCL1 fund IDYA1 fund INSM1 fund NTLA1 fund

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Related Research

Verdad's Biotech White Paper, Part 1: Why Specialist Fund Holdings Predict Returns

6 min read

Verdad's Biotech White Paper, Part 2: Why Traditional Quant Factors Fail — and What Works Instead

6 min read

Fund Convergence: The Highest-Conviction Signal in Biotech Investing

5 min read

Track specialist biotech funds, insider signals, and AI analysis

Start 14-Day Free Trial

Get free weekly alerts on fund moves and catalysts:

Terms

Privacy

Disclaimer